S&P 500   3,324.94 (-0.14%)
DOW   29,226.30 (-0.42%)
QQQ   223.59 (+0.09%)
AAPL   316.81 (-0.60%)
FB   221.17 (-0.44%)
MSFT   166.96 (-0.08%)
GOOGL   1,484.30 (+0.32%)
AMZN   1,884.93 (+1.08%)
GE   11.68 (-1.10%)
TSLA   545.68 (+6.89%)
AMD   51.17 (+0.45%)
T   38.57 (+0.50%)
ACB   2.00 (-6.10%)
NFLX   338.90 (-0.23%)
PRI   126.67 (-1.37%)
GILD   62.71 (-0.43%)
DIS   143.53 (-0.55%)
S&P 500   3,324.94 (-0.14%)
DOW   29,226.30 (-0.42%)
QQQ   223.59 (+0.09%)
AAPL   316.81 (-0.60%)
FB   221.17 (-0.44%)
MSFT   166.96 (-0.08%)
GOOGL   1,484.30 (+0.32%)
AMZN   1,884.93 (+1.08%)
GE   11.68 (-1.10%)
TSLA   545.68 (+6.89%)
AMD   51.17 (+0.45%)
T   38.57 (+0.50%)
ACB   2.00 (-6.10%)
NFLX   338.90 (-0.23%)
PRI   126.67 (-1.37%)
GILD   62.71 (-0.43%)
DIS   143.53 (-0.55%)
S&P 500   3,324.94 (-0.14%)
DOW   29,226.30 (-0.42%)
QQQ   223.59 (+0.09%)
AAPL   316.81 (-0.60%)
FB   221.17 (-0.44%)
MSFT   166.96 (-0.08%)
GOOGL   1,484.30 (+0.32%)
AMZN   1,884.93 (+1.08%)
GE   11.68 (-1.10%)
TSLA   545.68 (+6.89%)
AMD   51.17 (+0.45%)
T   38.57 (+0.50%)
ACB   2.00 (-6.10%)
NFLX   338.90 (-0.23%)
PRI   126.67 (-1.37%)
GILD   62.71 (-0.43%)
DIS   143.53 (-0.55%)
S&P 500   3,324.94 (-0.14%)
DOW   29,226.30 (-0.42%)
QQQ   223.59 (+0.09%)
AAPL   316.81 (-0.60%)
FB   221.17 (-0.44%)
MSFT   166.96 (-0.08%)
GOOGL   1,484.30 (+0.32%)
AMZN   1,884.93 (+1.08%)
GE   11.68 (-1.10%)
TSLA   545.68 (+6.89%)
AMD   51.17 (+0.45%)
T   38.57 (+0.50%)
ACB   2.00 (-6.10%)
NFLX   338.90 (-0.23%)
PRI   126.67 (-1.37%)
GILD   62.71 (-0.43%)
DIS   143.53 (-0.55%)
Log in

NASDAQ:ALEC - Alector Stock Price, Forecast & News

$22.00
+0.62 (+2.90 %)
(As of 01/21/2020 03:33 PM ET)
Today's Range
$20.99
Now: $22.00
$22.13
50-Day Range
$16.25
MA: $18.91
$21.38
52-Week Range
$13.64
Now: $22.00
$27.00
Volume243,243 shs
Average Volume292,568 shs
Market Capitalization$1.52 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALEC
CUSIPN/A
CIKN/A
Phone415-231-5660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.51 million

Profitability

Net Income$-52,250,000.00
Net Margins-378.57%

Miscellaneous

Employees91
Market Cap$1.52 billion
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive ALEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

Alector (NASDAQ:ALEC) Frequently Asked Questions

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

How were Alector's earnings last quarter?

Alector Inc (NASDAQ:ALEC) released its earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.07. The company earned $2.70 million during the quarter. Alector had a negative net margin of 378.57% and a negative return on equity of 58.27%. View Alector's Earnings History.

When is Alector's next earnings date?

Alector is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Alector.

What price target have analysts set for ALEC?

7 analysts have issued 1-year price objectives for Alector's stock. Their forecasts range from $26.00 to $28.00. On average, they expect Alector's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price. View Analyst Price Targets for Alector.

What is the consensus analysts' recommendation for Alector?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alector.

Has Alector been receiving favorable news coverage?

Press coverage about ALEC stock has been trending positive on Tuesday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alector earned a daily sentiment score of 2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Alector.

Are investors shorting Alector?

Alector saw a increase in short interest in December. As of December 31st, there was short interest totalling 4,280,000 shares, an increase of 19.2% from the December 15th total of 3,590,000 shares. Based on an average trading volume of 342,900 shares, the days-to-cover ratio is presently 12.5 days. Currently, 10.5% of the company's shares are sold short. View Alector's Current Options Chain.

Who are some of Alector's key competitors?

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), Verizon Communications (VZ), Cisco Systems (CSCO), Exxon Mobil (XOM), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), CVS Health (CVS), Altria Group (MO) and Precision BioSciences (DTIL).

Who are Alector's key executives?

Alector's management team includes the folowing people:
  • Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
  • Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
  • Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
  • Dr. Robert S. King, Chief Devel. Officer (Age 56)
  • Dr. Asa Abeliovich M.D., Ph.D., Co-Founder

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

Who are Alector's major shareholders?

Alector's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Alpine Global Management LLC (0.04%). Company insiders that own Alector stock include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul and Sabah Oney. View Institutional Ownership Trends for Alector.

Which institutional investors are buying Alector stock?

ALEC stock was acquired by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. View Insider Buying and Selling for Alector.

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $22.00.

How big of a company is Alector?

Alector has a market capitalization of $1.52 billion and generates $27.51 million in revenue each year. The company earns $-52,250,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Alector employs 91 workers across the globe.View Additional Information About Alector.

What is Alector's official website?

The official website for Alector is http://www.alector.com/.

How can I contact Alector?

Alector's mailing address is 151 OYSTER POINT BLVD. SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]


MarketBeat Community Rating for Alector (NASDAQ ALEC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  189
MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote "Outperform" if you believe ALEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel